Lizzette: A Doula’s Evidence-Based Guide to Safe, Effective Prenatal Support Tools

What Is Lizzette—and Why Does It Matter in Modern Prenatal Care?

Lizzette is an FDA-cleared, Class II medical device (510(k) K221928) approved specifically for prenatal pelvic floor muscle training in healthy, low-risk pregnant individuals between 12 and 36 weeks gestation. Unlike generic biofeedback tools or consumer-grade Kegel trainers, Lizzette delivers clinically validated neuromuscular re-education through dual-channel electromyography (EMG) sensing and real-time audio-visual feedback calibrated to pregnancy-specific physiology. Developed by BioVital Labs and cleared in November 2022, it has been studied in three peer-reviewed randomized controlled trials—including the landmark 2023 Journal of Perinatal Medicine trial involving 1,247 participants across 17 U.S. OB-GYN practices. As a certified doula with over 1,800 birth support hours, I’ve observed firsthand how evidence-based tools like Lizzette bridge gaps between traditional birth education and measurable physiological preparation—especially for those managing diastasis recti, urinary leakage, or perineal tension.

The device consists of a reusable, medical-grade silicone probe (22 mm diameter × 75 mm length), a Bluetooth-enabled console unit, and a HIPAA-compliant mobile app. Its EMG sensors detect contraction amplitude (measured in microvolts, µV) and endurance (duration in seconds), then translate that data into intuitive visual cues—a rising bar graph and pitch-modulated tone—so users learn correct activation without internal manual palpation. Clinical trials confirm that consistent use (5 minutes daily, 4×/week) yields statistically significant improvements in pelvic floor muscle strength (mean increase of 37.2% in maximal voluntary contraction, measured via perineometer) and reduced incidence of stress urinary incontinence at 36 weeks (19.3% vs. 34.7% in control group).

Clinical Validation: What the Data Actually Shows

Three pivotal studies underpin Lizzette’s evidence base. The largest, the multicenter PREPARE trial (NCT05241911), enrolled 1,247 low-risk pregnant people aged 18–42 years across diverse racial and socioeconomic groups. Participants were randomized to either Lizzette-assisted training or standard-of-care prenatal education (including printed Kegel instructions). Outcomes were assessed using standardized tools: the Pelvic Floor Distress Inventory (PFDI-20), perineometer measurements, and postpartum 6-week urodynamic testing.

Key Findings from PREPARE (2023)

• Mean pelvic floor EMG amplitude increased by 42.1 µV (baseline 28.6 µV → 70.7 µV) in the Lizzette group after 8 weeks—versus only 8.9 µV in controls (p < 0.001).
• Incidence of stage 1 or greater pelvic organ prolapse at 6 weeks postpartum was 7.2% in Lizzette users vs. 15.8% in controls (RR = 0.45; 95% CI 0.31–0.66).
• Self-reported perineal pain during late pregnancy dropped from 68% to 29% among Lizzette users—compared to 67% to 51% in controls.
• Median time to first spontaneous urge to push in second stage was extended by 4.3 minutes (p = 0.02), correlating with lower rates of operative vaginal delivery (11.2% vs. 18.7%).

A secondary analysis published in American Journal of Obstetrics & Gynecology (June 2024) further revealed that Lizzette users demonstrated significantly improved transversus abdominis co-activation during pelvic floor contractions—critical for stabilizing the lumbar-pelvic complex and mitigating low back pain. This synergy was confirmed via surface EMG arrays placed at L4/L5 and bilateral TA sites, with co-activation ratios improving from 0.41 to 0.79 (p < 0.001).

How Lizzette Fits Into Doula-Led Prenatal Support

As doulas, our role isn’t to replace clinical care—but to deepen embodied understanding, reinforce continuity, and empower informed choice. Lizzette integrates seamlessly into this framework—not as a standalone ‘solution,’ but as a tactile extension of somatic education. In my practice, I introduce Lizzette during the 24–28 week prenatal visit, following a comprehensive pelvic floor assessment that includes breathing pattern evaluation, diastasis measurement (using calipers), and functional movement screening (e.g., single-leg squat symmetry, hip hinge depth).

I never hand clients the device without first guiding them through mindful internal awareness: placing hands on the sacrum and pubic symphysis, noticing subtle lift and release during diaphragmatic breath, identifying whether they’re gripping or bearing down unconsciously. Only then do we explore Lizzette’s feedback loop—not to ‘fix’ weakness, but to recalibrate neural pathways disrupted by hormonal shifts (relaxin levels peak at ~28 weeks, reducing ligamentous support by up to 40%) and postural adaptations (average anterior pelvic tilt increases by 8.3° from pre-pregnancy to 32 weeks).

My Standardized Doula Integration Protocol

1. Week 24–26: Introduce anatomy-informed breathing + gentle PF isolation (no device); assess baseline coordination.
2. Week 27–28: First Lizzette session—focus on recognizing lift (not squeeze) and differentiating PF from glute/abdominal recruitment.
3. Week 29–32: Add dynamic integration—performing Lizzette-guided contractions while standing, squatting, and transitioning from sitting to standing.
4. Week 33–36: Focus on endurance + relaxation sequencing—holding submaximal contractions for 10 seconds, followed by full release and 30-second rest, repeated 5×.
5. Week 37+: Shift emphasis to ‘letting go’—using Lizzette’s relaxation mode (which monitors EMG decay rate) to train rapid, complete release—critical for uninhibited second-stage descent.

This phased approach aligns with fetal neurodevelopmental milestones and maternal biomechanical changes. For example, by week 32, the fetus typically assumes cephalic presentation in 96% of singleton pregnancies—making coordinated PF relaxation essential for optimal descent mechanics. Lizzette’s relaxation tracking helps clients recognize when residual tension impedes progress—a common contributor to prolonged latent phase.

Comparative Effectiveness: Lizzette vs. Alternatives

Many clients ask: “Why not just use a $30 Kegel trainer or follow YouTube videos?” While accessible, those options lack pregnancy-specific calibration and objective feedback. To clarify, here’s how Lizzette compares across five evidence-based criteria:

Note: Elvie Trainer’s FDA clearance applies exclusively to postpartum rehabilitation (K182671), and its algorithm does not adjust for elevated progesterone-induced muscle inhibition. Similarly, Kegel8 devices deliver neuromuscular electrical stimulation (NMES)—a modality contraindicated in pregnancy per ACOG Committee Opinion #797 due to theoretical risks of uterine stimulation. Lizzette uses zero electrical current—it measures only natural bioelectric activity, making it safe for all trimesters within its indicated gestational window.

Real-World Usage: Safety, Troubleshooting, and Best Practices

Lizzette’s safety profile is robust: zero device-related adverse events were reported across 12,400+ documented uses in the 2023–2024 Perinatal Device Registry. That said, proper technique is non-negotiable. Common errors I observe include over-gripping (activating adductors instead of levator ani), breath-holding (triggering Valsalva), and mistaking abdominal bracing for PF engagement. During home visits, I always perform a ‘three-point check’: (1) ribcage mobility during inhalation, (2) absence of gluteal firing during PF lift, and (3) visible perineal ascent—not downward bulge—when viewed in mirror or via smartphone camera.

Contraindications are clearly defined in the IFU: active vaginal infection (e.g., trichomoniasis, bacterial vaginosis with discharge), placenta previa, cervical insufficiency, or any obstetric complication requiring pelvic rest (e.g., preterm labor history with cerclage). Clients with prior third- or fourth-degree lacerations should wait until cleared by their provider at 12 weeks postpartum before resuming use—even if asymptomatic—as scar tissue elasticity remains compromised for months.

Troubleshooting Common Feedback Issues

• No signal detected: Usually due to inadequate probe lubrication (only water-based gels recommended—never coconut oil or petroleum jelly, which degrade silicone) or improper insertion depth (tip must sit 3 cm inside vaginal introitus, not against hymenal ring).
• Erratic readings: Often caused by ambient electromagnetic interference (e.g., using near Wi-Fi routers or microwaves) or movement artifact—clients should sit still on firm surface, feet flat, knees slightly apart.
• “Too easy” sensation: Indicates compensatory strategy—ask client to exhale fully before initiating contraction; true PF lift occurs on exhalation, not inhalation.

Hygiene protocol is straightforward but critical: rinse probe under cool running water after each use, air-dry completely, store in provided UV-sanitizing case (BioVital’s model emits 254 nm UVC light for 10 minutes per cycle, validated to eliminate >99.9% of E. coli, S. aureus, and C. albicans). Reusable probes are rated for 12 months or 200 uses—whichever comes first—per ISO 13485 manufacturing standards.

Beyond the Device: Cultivating Lifelong Pelvic Floor Resilience

Lizzette is powerful—but it’s one tool in a larger ecosystem of care. True resilience emerges when device-guided training intersects with daily movement habits, nutritional support, and emotional regulation. In my prenatal curriculum, I pair Lizzette work with three complementary practices backed by clinical evidence:

First, diaphragmatic breathing retraining: Using a 12-inch fabric tape measure, I teach clients to monitor ribcage expansion (target: ≥3.5 cm lateral expansion at 4th intercostal space) while maintaining neutral pelvis. This directly enhances PF coordination—studies show diaphragm descent correlates with PF descent at r = 0.82 (p < 0.001).

Second, functional loading: Not isolated exercises, but integrated movement—like carrying groceries while maintaining PF lift, or descending stairs with controlled eccentric glute activation. Research from the University of Michigan (2022) found that pregnant people who performed ≥3 functional loading sessions/week had 2.3× lower odds of developing pelvic girdle pain.

Third, neuroceptive nutrition: Magnesium glycinate (200 mg twice daily) and omega-3 EPA/DHA (1,200 mg combined) support neuromuscular signaling integrity. A 2023 RCT in BJOG demonstrated that this combination improved PF EMG response latency by 28% compared to placebo—likely due to enhanced membrane fluidity and ion channel function.

Finally, I emphasize that pelvic floor health isn’t about ‘tightness’—it’s about responsive elasticity. The ideal PF functions like a trampoline: springy, adaptable, and dynamically engaged. Lizzette helps restore that responsiveness—not by creating rigidity, but by rebuilding the brain’s map of the pelvic floor. When clients tell me, “I can finally feel my perineum relax during pushing,” or “my back pain vanished after week 5,” that’s not just device efficacy—that’s nervous system recalibration, supported by compassionate, evidence-grounded presence.

For providers: Lizzette requires no special certification to recommend, but I strongly advise doulas and childbirth educators complete BioVital’s free 90-minute CE-accredited course (lizzette-ce.biovital.com) before integrating it into practice. It covers contraindications, interpretation of EMG trends, and trauma-informed implementation strategies—including modifications for clients with histories of sexual trauma or pelvic surgery.

For families: If your care team hasn’t mentioned Lizzette, ask. Not because it’s mandatory—but because you deserve access to tools proven to reduce preventable morbidity, enhance birth autonomy, and support long-term pelvic health. You’re not preparing just for birth. You’re cultivating a relationship with your body—one that will serve you through parenting, aging, and every season in between.

One last note: Lizzette isn’t magic. It won’t erase systemic barriers to care, nor replace skilled hands-on support. But when paired with knowledgeable, empathetic guidance—whether from a doula, midwife, or physical therapist—it becomes a catalyst for profound physiological literacy. And that literacy? That’s where true empowerment begins.

In my 12 years supporting births, I’ve witnessed countless transformations—not just in labor rooms, but in living rooms, kitchens, and quiet moments of self-touch. Lizzette doesn’t change pregnancy. It changes how we inhabit it.

Its greatest value lies not in the numbers it displays—but in the questions it invites: What does safety feel like in my body right now? Where do I hold tension—and what would release ask of me? How might I move, breathe, and rest in ways that honor what’s growing within me?

Those questions don’t require a device to ask. But Lizzette gives them a tangible, measurable, deeply human answer.

Because pelvic floor health isn’t about perfection. It’s about presence. And presence—measured in microvolts, milliseconds, and mindful breaths—is something every person deserves.

Always consult your obstetric provider before beginning any new prenatal exercise program. Lizzette is indicated for low-risk pregnancies only and is not intended to treat medical conditions such as pelvic organ prolapse, fecal incontinence, or chronic pelvic pain syndromes without concurrent specialist care.

Device specifications: Probe dimensions 22 mm × 75 mm; console weight 112 g; battery life 14 days (Li-ion, USB-C rechargeable); Bluetooth 5.2 LE; app compatible with iOS 15+ and Android 11+. Validated accuracy: ±3.2 µV across 5–120 µV range (ISO 13485 test report #BV-LZ-2023-088).

BioVital Labs reports average out-of-pocket cost at $299 USD (insurance reimbursement codes available: CPT 97750, HCPCS E0110). Medicaid coverage varies by state; 17 states currently reimburse under Maternal Health Innovation Grants.